Project Grant R61CA302620
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), is focused on developing a novel high-throughput, high-content imaging platform for analyzing extracellular vesicles (EVs) at the single-particle level. The $298,999 award to Numentus Technologies Inc. will fund the construction, testing, and application of this platform to detect and characterize EV subpopulations, including...
- The National Cancer Institute (NCI) awarded a $2,855,619 Project Grant titled "Empowering Cancer Detection and Monitoring with CAMPEX - CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles" to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), aims to advance CAMPEX, an integrated platform for highly sensitive and precise analysis of...
- This Project Grant award, in the amount of $1,221,128.00, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Massachusetts Boston. The funding will support a 3-year research project to investigate the biomechanical and biomolecular properties of large extracellular vesicles (L-EVs), which play important roles in cell-to-cell communication and have potential as disease biomarkers and therapeutic carriers. The research team, with...
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of extracellular vesicles (EVs) as therapeutic carriers. The $622,000 award, effective August 1, 2024 through July 31, 2027, will enable researchers at The Washington University in St. Louis to engineer endothelial cell-derived EVs to efficiently...
- This Project Grant award of $231,413 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a novel SPINEX (Separation-Processing Integration for Extracellular Vesicles) technology to streamline sample preparation for extracellular vesicle (EV) analysis. The project, awarded to The General Hospital Corporation (doing business as Massachusetts General Hospital), has two key objectives: Implement a fully automated, multi-functional SPINEX...
- This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...
- This federal Project Grant award of $418,176 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel approach called "Programmable Nucleic Acid Cytometry" at the Sloan-Kettering Institute for Cancer Research. The project aims to advance this innovative method for profiling rare cell populations from tumors and tissues, which offers advantages over traditional antibody-based cell isolation techniques. The work will...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- This federal Project Grant award of $672,371.00 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research at Yale University to develop ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics. The project aims to improve the identification of tumor-specific antigens (TSAs) to support the development of effective cancer immunotherapies. The award has a performance period from September 1, 2025...
This $625,756 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a high-throughput microfluidic platform called "Agarose Bead-based Digital Single Molecule-Single EV Sorting (BDEVS)" for ultra-sensitive profiling of individual extracellular vesicles (EVs) in plasma. The platform utilizes rolling circle amplification and flow cytometry-based readout/sorting to enable multiplexed, single-molecule quantification of EV surface proteins, addressing prior limitations in EV analysis. This research aims to advance the clinical translation of EV biomarkers for cancer and other diseases by providing a novel, high-throughput approach to characterize the molecular cargo of individual EVs. The award was granted to the University of Pennsylvania and has an ultimate completion date of July 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $625.8k | 8/11/25 |